Skip to the answer

Fedratinib Uses, Dosage, Side Effects and Interactions

Brand name
Inrebic

Inrebic was the first fedratinib product the FDA approved, in August 2019. No generic is listed as capsules.

First generic of Inrebic: our estimate, 2033 to 2034

Fedratinib is a once-daily oral kinase inhibitor used to treat adults with intermediate-2 or high-risk primary or secondary myelofibrosis, a bone marrow disorder.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About FedratinibType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Fedratinib in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Fedratinib (Inrebic) is a JAK2 inhibitor that blocks an overactive enzyme driving myelofibrosis (a bone marrow disease) in adults with intermediate-2 or high-risk disease; it is a specialist drug, used first or after ruxolitinib, on the market since about 2019 and not available as a generic. Stomach upset is the main complaint (diarrhea, nausea, vomiting), and tiredness and low red cell and platelet counts are common too. The boxed warning is for encephalopathy, including Wernicke's, a brain emergency tied to low thiamine (vitamin B1); confusion, memory trouble, unsteady walking or double vision need emergency care. Never stop it suddenly on your own, since symptoms can flare.

Key Takeaways From the HelloPharmacist Team

  • Take it once a day with or without food, and if you miss a dose, just take the next day's dose.
  • Take a thiamine (vitamin B1) supplement every day, and expect regular blood tests for thiamine, blood counts and liver and pancreas enzymes.
  • Have an anti-nausea and anti-diarrhea medicine on hand from day one, and call your doctor if diarrhea or vomiting lasts beyond 48 hours.
  • Check every new medicine with your pharmacist first, since common ones like fluconazole, omeprazole, metoprolol and metformin can need dose changes.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Fedratinib.

Inrebic can cause serious, sometimes fatal brain problems called encephalopathy, including Wernicke's encephalopathy. This is a neurologic emergency caused by low thiamine (vitamin B1).

Your doctor should check your thiamine level before you start. Inrebic should not be started if you are deficient. You should take a thiamine supplement every day during treatment, with levels rechecked as needed. Watch for confusion, memory trouble, changes in alertness, unsteady walking, or eye movement problems and double vision. If any of these occur, get medical help immediately. Treatment is stopped and thiamine is given by injection or IV.

Read the full warning on DailyMed →

Fedratinib by the Numbers

Strengths
1
in one form
Makers and packagers
1
Earliest FDA record
2019

Patient Information Guide for Fedratinib

What It’s Used For

Fedratinib is used for one condition, myelofibrosis, in adults.

  • Inrebic is used for intermediate-2 or high-risk primary myelofibrosis.
  • Inrebic is also used for secondary myelofibrosis that developed after polycythemia vera or essential thrombocythemia.

How It Works

Fedratinib is a kinase inhibitor, meaning it blocks enzymes that send growth signals inside cells. It is selective for JAK2, which is abnormally active in myelofibrosis and related bone marrow disorders. It also acts against FLT3.

In lab and animal studies, blocking these signals reduced abnormal cell growth and improved spleen size, scarring and survival.

Drug Class

WHO drug family

  • Janus-associated kinase (JAK) inhibitors
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)

None. The FDA’s index lists no class of any kind for Fedratinib.

The main drug class the FDA gives it. It is the class named on the drug’s label.

What It Does in the Body

Physiologic effect (PE)

None listed for Fedratinib in the FDA’s index.

From our Patient Information GuideFedratinib is a kinase inhibitor, meaning it blocks enzymes that send growth signals inside cells. It is selective for JAK2, which is abnormally active in myelofibrosis and related bone marrow disorders. It also acts against FLT3. Read How Fedratinib Works

A change it makes in how the body works.

Drug Family

WHO ATC classification
  • Janus-associated kinase (JAK) inhibitors

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification, from the U.S. National Library of Medicine’s RxClass. Reference only, not medical advice.

Dosage

Inrebic is a capsule taken by mouth once daily, with or without food. A high-fat meal may ease nausea and vomiting.

Your doctor will check your platelet count and other labs before and during treatment.

  • You will take thiamine (vitamin B1) daily while on treatment.
  • Missed a dose? Take your next dose the following day.
  • If you cannot swallow capsules, the contents can be mixed with Ensure Plus and taken within 2 hours.
  • Your dose may be lowered for strong CYP3A4 inhibitor use, severe kidney impairment, or side effects.

Follow your prescriber's directions and the label.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Myelofibrosis (a bone marrow disease)

Adults Usual dose 400 mg once a day
  • 400 mg taken orally once daily, with or without food (capsules 100 mg each)

Good to know

Thiamine 100 mg orally daily prophylaxis for all patients

Adults taking strong CYP3A4 inhibitor medicines Starting dose 200 mg once a day
  • If the inhibitor is stopped, increase to 300 mg once daily during the first two weeks after discontinuation, then to 400 mg once daily thereafter as tolerated

Good to know

Strong CYP3A4 inhibitor coadministration

Adults with low platelet counts Dose 100 mg daily
  • Interrupt dose until resolved to Grade 2 or lower or baseline.
  • Restart dose at 100 mg daily below the last given dose.

Good to know

Discontinue if unable to tolerate 200 mg daily

Adults with low neutrophil counts Dose 100 mg daily
  • Interrupt dose until resolved to Grade 2 or lower or baseline.
  • Restart dose at 100 mg daily below the last given dose.

Good to know

Consider dose reductions for patients who become transfusion-dependent

Adults with severe nausea, vomiting or diarrhea Dose 100 mg daily
  • Interrupt dose until resolved to Grade 1 or lower or baseline.
  • Restart dose at 100 mg daily below the last given dose.
Adults with other severe side effects Dose 100 mg daily
  • Interrupt dose until resolved to Grade 1 or lower or baseline.
  • Restart dose at 100 mg daily below the last given dose.
Adults with severe kidney problems Usual dose 200 mg once a day

Good to know

CLcr 15 mL/min to 29 mL/min by Cockcroft-Gault

CrCl means creatinine clearance, a measure of how well the kidneys work.

Special Situations

If your test results change during treatment

Your doctor checks your test results during treatment and decides whether to change, pause or stop your dose. Never change your dose on your own.

Grade 3 or higher ALT, AST, or bilirubin elevation

Interrupt dose until resolved to Grade 1 or lower or baseline. Restart dose at 100 mg daily below the last given dose.

Monitor ALT, AST, and bilirubin more frequently; if Grade 3 or higher elevation recurs, discontinue Inrebic

ALT means alanine aminotransferase, a liver enzyme measured in a blood test.

AST means aspartate aminotransferase, a liver enzyme measured in a blood test.

See the Full Dosing Instructions on DailyMed →

Side Effects

The most common side effects are stomach-related and blood-related.

Common side effects

  • Diarrhea
  • Nausea
  • Vomiting
  • Anemia (low red blood cells)
  • Fatigue
  • Low platelets (thrombocytopenia)
  • Constipation
  • Muscle spasms

When to get medical help

  • Get emergency help right away for confusion, memory problems, changes in alertness, unsteady walking, or eye movement problems or double vision. These can be signs of Wernicke's encephalopathy.
  • Call your doctor if you have severe or ongoing diarrhea, nausea or vomiting, especially if it does not improve within 48 hours.
  • Call your doctor about unusual bleeding or bruising, or signs of severe anemia such as marked tiredness.
  • Tell your doctor promptly about eye pain, redness, sensitivity to light, floaters or decreased vision. These can be signs of uveitis (eye inflammation).
  • Seek help for symptoms of blood clots, heart attack or stroke.
  • Call your doctor if you have yellowing of the skin or eyes or severe stomach pain, which may point to liver or pancreas problems.
  • Do not stop Inrebic suddenly on your own. Symptoms can flare, including fever, trouble breathing and low blood pressure.

Warnings and Precautions

  • Encephalopathy including Wernicke's: a serious, sometimes fatal brain problem tied to low thiamine. Daily thiamine and lab checks are required.
  • Low blood counts: anemia and low platelets are common and may need dose changes or transfusions.
  • Stomach upset: very common, and anti-nausea and anti-diarrhea medicines are often used.
  • Liver, amylase and lipase increases: monitored with blood tests.
  • Uveitis: eye inflammation that can show up months into treatment.
  • Heart events, clots and secondary cancers: seen with another drug in this class in rheumatoid arthritis. Risk is higher in current or past smokers.
  • Stopping suddenly: symptoms can flare, so talk to your care team first.

Interactions

Many interactions involve how the liver processes fedratinib.

  • Strong CYP3A4 inhibitors (such as ketoconazole): raise fedratinib levels, so a lower dose may be needed.
  • Strong and moderate CYP3A4 inducers (such as rifampin, efavirenz): lower levels and may reduce effectiveness, so avoid them.
  • Fluconazole: raises levels, so closer monitoring is needed.
  • Drugs cleared by CYP3A4, CYP2C19 or CYP2D6: levels may rise, so doses may need adjusting.
  • Metformin and similar drugs cleared by the kidneys: may build up, so doses may need adjusting.
  • Ruxolitinib: must be tapered off before starting Inrebic.

Interactions Listed in the FDA-Approved Label

From the Fedratinib prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A4 inhibitors
    What happensIncrease fedratinib exposure, which may increase the risk of adverse reactions.
    What to doConsider alternative therapies that do not strongly inhibit CYP3A4; alternatively reduce the INREBIC dose.
  • Strong and moderate CYP3A4 inducers
    What happensCan decrease fedratinib exposure and may reduce effectiveness of INREBIC.
    What to doAvoid use with INREBIC.
  • Dual CYP3A4 and CYP2C19 inhibitors
    What happensIncrease fedratinib exposure, which may increase the risk of adverse reactions.
    What to doMore intensive safety monitoring and, if necessary, INREBIC dose modifications based on adverse reactions.
  • CYP3A4, CYP2C19, or CYP2D6 substrate drugs
    What happensINREBIC increases the concentrations of these drugs, which may increase their adverse reactions.
    What to doMonitor for adverse reactions and adjust the dose of these drugs as necessary.
  • OCT2 and MATE1/2-K substrate drugs For example: metformin
    What happensINREBIC can decrease renal clearance of these drugs.
    What to doMonitor for adverse reactions and consider dose modifications of these drugs as necessary.
Read the label’s full interactions text

7 DRUG INTERACTIONS • Strong CYP3A4 Inhibitors: Reduce INREBIC dose as recommended. • Strong and Moderate CYP3A4 Inducers: Avoid use of INREBIC. • CYP3A4, CYP2C19, or CYP2D6 Substrates: Dose modifications of substrates drugs may be needed. • OCT2 and MATE1/2-K Substrates: Dose modifications of substrate drugs may be needed. 7.1 Effect of Other Drugs on INREBIC Strong CYP3A4 Inhibitors Coadministration of INREBIC with a strong CYP3A4 inhibitor increases fedratinib exposure. Increased exposure may increase the risk of adverse reactions. Consider alternative therapies that do not strongly inhibit CYP3A4 activity. Alternatively, reduce the dose of INREBIC when administering with a strong CYP3A4 inhibitor. Strong and Moderate CYP3A4 Inducers Coadministration of INREBIC with a strong or moderate CYP3A4 inducer can decrease fedratinib exposure. Decreased exposure may reduce the effectiveness of INREBIC. Avoid INREBIC with strong and moderate CYP3A4 inducers. Dual CYP3A4 and CYP2C19 Inhibitors Coadministration of INREBIC with a dual CYP3A4 and CYP2C19 inhibitor increases fedratinib exposure. Increased exposure may increase the risk of adverse reactions. Due to potential increase of exposure, patients taking concomitant dual CYP3A4 and CYP2C19 inhibitors require more intensive safety monitoring and, if necessary, dose modifications of INREBIC based on adverse reactions. 7.2 Effect of INREBIC on Other Drugs CYP3A4, CYP2C19, or CYP2D6 Substrate Drugs Coadministration of INREBIC with drugs that are CYP3A4 substrates, CYP2C19 substrates, or CYP2D6 substrates increases the concentrations of these drugs, which may increase the risk of adverse reactions of these drugs.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • There are no listed contraindications.
  • Thiamine must be checked and corrected before starting.
  • Severe kidney impairment needs a lower dose, and moderate impairment needs closer monitoring.
  • Pregnancy: no human data, and animal studies showed developmental effects. Your doctor will weigh benefits and risks.
  • Do not breastfeed during treatment and for at least 1 month after the last dose.
  • Not established for children.
  • Older adults had no overall differences in safety or effectiveness.
  • Tell your doctor if you smoke or have a history of cancer, heart disease or clots.

Overdose

If you take too much Inrebic, consider contacting the Poison Help line at 1-800-222-1222 or a medical toxicologist for guidance.

Half-Life and How Your Body Processes It

Fedratinib reaches peak levels about 3 hours after a dose and builds up to steady levels within about 15 days of daily dosing. Food changes absorption only modestly. It is broken down mainly by liver enzymes (CYP3A4, CYP2C19 and FMO3) and cleared mostly in the feces. It has a long effective half-life of about 41 hours, and a terminal half-life of about 114 hours. Levels are higher in people with moderate to severe kidney impairment.

Storage

Store below 30°C (86°F).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Supplements and Herbs That Interact With Fedratinib

From the licensed clinical database we use, rolled up per supplement, most serious first.

177 supplements and herbal products have documented interactions with Fedratinib in the licensed clinical database we use.

Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.

  • 6Major
  • 132Moderate
  • 39Minor

See the other 169

Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Fedratinib: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Fedratinib — the kind of thing our pharmacy team would talk through with you at the counter.

What is fedratinib used for?

Fedratinib, sold as Inrebic, treats adults with intermediate-2 or high-risk myelofibrosis. That includes primary myelofibrosis and the type that follows polycythemia vera or essential thrombocythemia. It works by blocking an overactive enzyme called JAK2 that drives the disease.

What happens if I miss a dose of fedratinib?

If you miss a dose, just take your next scheduled dose the following day. Don't double up. If you're unsure, check with me or your prescriber.

Why do I have to take thiamine with fedratinib?

Fedratinib can cause serious brain problems called Wernicke's encephalopathy, which comes from low vitamin B1 (thiamine). Taking thiamine daily lowers that risk, and your doctor will check your levels. Get help right away if you notice confusion, memory trouble, unsteady walking or double vision.

What side effects should I expect with fedratinib?

Diarrhea, nausea and vomiting are very common, usually starting in the first couple of weeks. Anemia and low platelets are also common, so you'll have regular blood tests. Call your doctor if stomach symptoms are severe or don't improve within 48 hours, and ask about anti-nausea and anti-diarrhea medicines.

Can I stop fedratinib suddenly?

Please don't stop it on your own. After stopping drugs like this, myelofibrosis symptoms can flare, and some people have had fever, trouble breathing or low blood pressure. Your doctor may taper the dose gradually.

Can I take fedratinib with other medicines or while pregnant or breastfeeding?

Always show me your full medicine list. Some antifungals like ketoconazole raise fedratinib levels, and drugs like rifampin or efavirenz lower them. There are no human pregnancy data, and animal studies showed harm, so talk to your doctor if you could become pregnant. You shouldn't breastfeed during treatment and for at least 1 month after your last dose.

Is fedratinib available over the counter?

No. Fedratinib is a prescription medicine: every fedratinib product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was fedratinib first available?

The earliest FDA record we hold for fedratinib is from 2019: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when fedratinib was first used.

What is the brand name of fedratinib?

Fedratinib is the generic name. Its brand name is Inrebic.

What is the generic name of Inrebic?

The generic name of Inrebic is fedratinib. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What strengths does fedratinib come in?

Fedratinib is listed in the FDA's National Drug Code Directory in these forms and strengths. Capsule (by mouth): 100 mg. A listing does not mean every pharmacy stocks every strength.

Is there a fedratinib shortage?

No. Fedratinib is not on the FDA's drug shortage list as of Nov 22, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the fedratinib prescribing information (package insert)?

The full FDA-approved prescribing information for fedratinib, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Celgene Corporation's, revised Jul 20, 2026, and links to it on DailyMed.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Fedratinib

Skip the scrolling. Ask in your own words and get an answer from Fedratinib’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Fedratinib’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Fedratinib on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Fedratinib Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Fedratinib Forms and Strengths (How It Comes)

Fedratinib comes in 1 dose form, the capsule. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Fedratinib inactive ingredients by manufacturer.

Capsule

By mouth
Brands Inrebic (the first brand, 2019)
How this form is used
What it may be used for
  • Inrebic is used for adults with intermediate-2 or high-risk primary or secondary myelofibrosis.
Important instructions
  • Inrebic is taken by mouth once daily, with or without food.
  • Inrebic taken with a high-fat meal may reduce nausea and vomiting.
  • If you cannot swallow Inrebic capsules whole or have a nasogastric tube, the contents can be mixed with Ensure Plus and given within 2 hours.
  • If an Inrebic dose is missed, take the next dose the following day.
Available strengths 1 strength
1 FDA-listed product record ⓘ

Fedratinib on the U.S. Market: Products, Makers and Brands

How Fedratinib appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 1 Fedratinib product record with the FDA, mostly as capsule; the earliest marketing or approval year on record is 2019. The one brand name in the directory today is Inrebic; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
1
FDA-listed product records ⓘ
2019
Earliest FDA record ⓘ

Compare Fedratinib Products

A representative set of FDA-listed product records for Fedratinib — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Capsule
100 mg Oral Celgene Corporation NDA View NDC →

Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Fedratinib NDCs →

Fedratinib Side Effects Reported to the FDA (FAERS)

After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Fedratinib — a signal of what to watch for, not proof the drug caused it.

The effects most often named in FDA reports that mention Fedratinib are diarrhoea, death, nausea; about 51% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.

1,349
Reports mentioning it
51%
Reported as serious
12
Distinct effects shown
Most reported effects
Diarrhoea
146
Death
141
Nausea
122
Fatigue
115
Vomiting
73
Constipation
59
Haemoglobin Decreased
54
Asthenia
52
Platelet Count Decreased
50
Full Blood Count Decreased
45
Age groups
Elderly · 435Adult · 123

Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Fedratinib in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.

Fedratinib FDA Approval History

How Fedratinib went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.

Fedratinib was first approved by the FDA in 2019 (Brand: INREBIC · Bristol-myers). It remains available in U.S. pharmacies today.

2019
Brand approved
Brand: INREBIC · Bristol-myers
2026
Available today
Active in U.S. pharmacies

Source: Drugs@FDA.

Fedratinib Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Fedratinib recalls since July 2021.

✅No Fedratinib recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Fedratinib in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
1
Strengths
1
Forms in current FDA listings
1 of 1
In current FDA listings No current FDA listing
Ingredient (IN) Fedratinib RxCUI 2197490
  1. Dose form (SCDF) Oral Capsule RxCUI 2197494
    In current FDA listings
    Its strength (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Fedratinib Brand Names

Fedratinib has one brand name on record: Inrebic. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Inrebic the first brand, 2019

Who Makes Fedratinib: Manufacturers and Labelers

One company lists Fedratinib products with the FDA. By number of product records, the largest are Celgene Corporation. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Celgene Corporation 1

Sources for This Fedratinib Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jul 20, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Fedratinib.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
1
Finished products in the current FDA directory
1
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Celgene Corporation
Linked label effective
Jul 20, 2026
Composite sections available
24
Linked SPL Set ID
f0f55a2a-4e0c-4cba-8571-03e1424486d7
Linked SPL Document ID
c328016b-fc3e-4d6f-99b3-8d2c13b362f3
Open the linked representative label on DailyMed ↗
NDC package records associated with this linked SPL 1

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Celgene Corporation is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →